Stock Scorecard
Stock Summary for Emergent Biosolutions Inc (EBS) - $12.96 as of 1/9/2026 7:39:32 PM EST
Total Score
13 out of 30
Safety Score
47 out of 100
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for EBS
| Positive Quarterly and Annual earnings growth | |
| P/E ratio less than Industry P/E Ratio | |
| P/E ratio less than Sector P/E Ratio | |
| P/E ratio that is half the Annual earnings growth rate (or less) | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Positive net income past year and 12 trailing months | |
| Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for EBS
| Revenue growing by at least 20% average per year over the last 5 years | |
| Market Capitalization under 2 billion | |
| Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
| Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
| Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for EBS
| Declared an ex-dividend date | |
| Forward annual dividend rate greater than 2 | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Current ratio most recent quarter greater than 2 | |
| Cash Flow per Share greater than Trailing Dividend Rate |
Bonus Criteria for EBS
| P/E ratio less than five-year Average P/E ratio | |
| Last Price to 52 Week Low Ratio Less Than 1 | |
| Total Cash Per Share > Last Day Price | |
| P/S Ratio < 1 | |
| P/B Ratio < 1 |
Safety Rating Criteria for EBS (47 out of 100)
| Stock Price Rating (Max of 10) | 5 |
| Historical Stock Price Rating (Max of 10) | 5 |
| Stock Price Trend (Max of 10) | 7 |
| Book Value (Max of 10) | 5 |
| Book Value to Price (Max of 10) | 1 |
| Analyst Buy Ratings (Max of 5) | 3 |
| Analyst Strong Buy Ratings (Max of 5) | 0 |
| Dividend Yield Percentage (Max of 10) | 0 |
| Operating Margin (Max of 10) | 6 |
| Trading Volume (Max of 10) | 6 |
| Price to Earnings (Max of 10) | 9 |
| Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) | 0 |
Financial Details for EBS
Company Overview |
|
|---|---|
| Ticker | EBS |
| Company Name | Emergent Biosolutions Inc |
| Country | USA |
| Description | Emergent BioSolutions Inc. (EBS), headquartered in Gaithersburg, Maryland, is a leading life sciences firm dedicated to enhancing public health preparedness through its innovative vaccines, therapeutics, and diagnostics. The company plays a crucial role in addressing significant health threats, including emerging infectious diseases and bioterrorism, by providing advanced solutions tailored for both civilian and military applications. With a robust commitment to health security and a strategic focus on meeting urgent global health needs, Emergent is uniquely positioned to support governmental emergency response efforts and contribute to the resilience of public health systems worldwide. |
| Sector Name | HEALTHCARE |
| Industry Name | DRUG MANUFACTURERS - SPECIALTY & GENERIC |
| Most Recent Quarter | 9/30/2025 |
| Next Earnings Date | 3/10/2026 |
Stock Price History |
|
| Last Day Price | 12.96 |
| Price 4 Years Ago | 11.81 |
| Last Day Price Updated | 1/9/2026 7:39:32 PM EST |
| Last Day Volume | 616,660 |
| Average Daily Volume | 817,071 |
| 52-Week High | 14.06 |
| 52-Week Low | 4.02 |
| Last Price to 52 Week Low | 222.39% |
Valuation Measures |
|
| Trailing PE | 9.96 |
| Industry PE | 33.56 |
| Sector PE | 55.07 |
| 5-Year Average PE | -0.44 |
| Free Cash Flow Ratio | 2.78 |
| Industry Free Cash Flow Ratio | 13.48 |
| Sector Free Cash Flow Ratio | 32.93 |
| Current Ratio Most Recent Quarter | 5.76 |
| Total Cash Per Share | 4.67 |
| Book Value Per Share Most Recent Quarter | 11.05 |
| Price to Book Ratio | 1.16 |
| Industry Price to Book Ratio | 3.97 |
| Sector Price to Book Ratio | 37.07 |
| Price to Sales Ratio Twelve Trailing Months | 0.89 |
| Industry Price to Sales Ratio Twelve Trailing Months | 2.91 |
| Sector Price to Sales Ratio Twelve Trailing Months | 12.84 |
| Analyst Buy Ratings | 2 |
| Analyst Strong Buy Ratings | 0 |
Share Statistics |
|
| Total Shares Outstanding | 52,520,000 |
| Market Capitalization | 680,659,200 |
| Institutional Ownership | 76.47% |
Dividends |
|
| Ex-Dividend Date | N/A |
| Previous Dividend Amount | 0.0000 |
| Current Dividend Amount | 0.0000 |
| Total Years Dividend Increasing | N/A |
| Trailing Annual Dividend Rate | 0.00 |
| Trailing Annual Dividend Yield | 0.79% |
| Forward Annual Dividend Rate | 0.00 |
| Forward Annual Dividend Yield | 0.00% |
| 5-Year Dividend Payments Count | 0 |
| 3-Year Average Dividend Yield | 0.00% |
| 5-Year Average Dividend Yield | 0.00% |
| 1-Year Dividend Growth Rate Percentage | 0.00% |
| 3-Year Dividend Growth Rate Percentage | 0.00% |
| 5-Year Dividend Growth Rate Percentage | 0.00% |
| All-Time Dividend Growth Rate Percentage | 0.00% |
| Dividend Payout Ratio | N/A |
Income Statement |
|
| Quarterly Earnings Growth YOY | -55.80% |
| Annual Earnings Growth | 74.94% |
| Reported EPS 12 Trailing Months | 1.32 |
| Reported EPS Past Year | 1.93 |
| Reported EPS Prior Year | -0.94 |
| Net Income Twelve Trailing Months | 75,900,000 |
| Net Income Past Year | -190,600,000 |
| Net Income Prior Year | -760,500,000 |
| Quarterly Revenue Growth YOY | -21.30% |
| 5-Year Revenue Growth | -1.15% |
| Operating Margin Twelve Trailing Months | 37.80% |
Balance Sheet |
|
| Total Cash Most Recent Quarter | 245,500,000 |
| Total Cash Past Year | 99,500,000 |
| Total Cash Prior Year | 111,700,000 |
| Net Cash Position Most Recent Quarter | -417,600,000 |
| Net Cash Position Past Year | -564,200,000 |
| Long Term Debt Past Year | 663,700,000 |
| Long Term Debt Prior Year | 446,500,000 |
| Total Debt Most Recent Quarter | 663,100,000 |
| Equity to Debt Ratio Past Year | 0.42 |
| Equity to Debt Ratio Most Recent Quarter | 0.47 |
| Total Stockholder Equity Past Year | 482,800,000 |
| Total Stockholder Equity Prior Year | 649,300,000 |
| Total Stockholder Equity Most Recent Quarter | 582,500,000 |
Free Cash Flow |
|
| Free Cash Flow Twelve Trailing Months | 1,400,000 |
| Free Cash Flow Per Share Twelve Trailing Months | 0.03 |
| Free Cash Flow Past Year | 35,800,000 |
| Free Cash Flow Prior Year | -257,900,000 |
Options |
|
| Put/Call Ratio | 0.07 |
| Has Options | Options Chain |
| Liquidity Rating | |
Technical Analysis |
|
| Yahoo Finance Chart | Yahoo Finance Chart |
| MACD | 0.53 |
| MACD Signal | 0.46 |
| 20-Day Bollinger Lower Band | 6.86 |
| 20-Day Bollinger Middle Band | 10.31 |
| 20-Day Bollinger Upper Band | 13.76 |
| Beta | 2.31 |
| RSI | 72.93 |
| 50-Day SMA | 0.00 |
| 150-Day SMA | 0.00 |
| 200-Day SMA | 11.53 |
System |
|
| Modified | 1/7/2026 9:50:41 PM EST |